Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




ML-Powered Gas Sensors to Detect Pathogens and AMR at POC

By LabMedica International staff writers
Posted on 24 Jul 2025

Fast and accurate diagnosis is critical to improving patient care and combating the global threat of antimicrobial resistance (AMR). More...

Traditional diagnostic methods for infections, such as gas chromatography-mass spectrometry and proton transfer reaction–mass spectrometry, while effective, are expensive, technically demanding, and unsuitable for point-of-care settings. Interpreting volatile organic compounds (VOCs)—the unique chemical signatures emitted by microbes and infected tissues—can be challenging due to their complexity and overlap. Moreover, these VOC signals are often influenced by environmental variables, which adds to diagnostic inaccuracy. A report published in Cell Biomaterials explores the use of sensor systems combined with advanced computational models to detect and classify microbial VOCs with high precision.

This report by researchers at ETH Zurich (Zurich, Switzerland) presents a promising approach that combines gas sensors and machine learning for real-time infection diagnosis. The report explores how gas sensors made from nanostructured metal oxides, conductive polymers, and hybrid composites could offer a compact, affordable, and practical solution for detecting VOCs. These sensors measure changes in electrical resistance or conductance when exposed to microbial byproducts. To decode the complex patterns produced by VOCs, the researchers assessed the viability of integrating machine learning algorithms such as support vector machines (SVM), random forests, long short-term memory (LSTM) neural networks, and gradient boosting to classify sensor data and improve diagnostic accuracy. The models were assessed across bacterial cultures, infected tissues, and clinical biofluids such as urine and blood, demonstrating its ability to distinguish bacterial species and differentiate between drug-resistant and susceptible strains.

The team compiled findings from recent studies that tested these sensor-ML systems on bacterial cultures, infected tissue samples, and clinical biofluids such as urine and blood. The systems achieved high sensitivity and specificity, accurately identifying pathogens like Escherichia coli and Staphylococcus aureus, as well as detecting resistance profiles such as those involving extended-spectrum beta-lactamases. The researchers have emphasized the need for training these machine learning models on comprehensive datasets that reflect clinical variability to ensure robust performance. Ongoing efforts include miniaturizing devices for point-of-care use, functionalizing sensor surfaces, and mitigating environmental interference such as humidity and temperature. Although further development and clinical validation are necessary, these systems offer a clear path toward noninvasive, rapid diagnostics that can complement laboratory methods and support better antimicrobial stewardship.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.